Our NIH-funded research laboratory studies the biophysical mechanisms of cardiac conduction and arrhythmia, and has developed novel anti-arrhythmia therapies, including low-energy defibrillation therapy. The lab works on future treatments for the heart rhythm disorders and on engineering the pacemaker and conduction system of the heart, using electrical engineering, molecular biology, and multimodal imaging techniques.
Dr Efimov co-founded a company, Cardialen, Inc. in 2008. The company goal is to develop pain-free cardioversion therapy, with a primary focus on atrial fibrillation. It is commercializing our laboratory's technology to develop implantable low-energy (low voltage) pain-free atrial cardioverters. Dr. Efimov serves as a Director, Chief Scientific Advisor and Chair of the Cardialen Scientific Advisory Board.
- PhD from Moscow Institute of Physics and Technology (1992)
- Postdoc (1992-1994) University of Pittsburgh
- Cleveland Clinic (1994-2000)
- Case Western Reserve University (2000-2004)
- Washington University in St. Louis (2004-2015)
- The George Washington University (2015-present)